Evaluation of the effectiveness of sugammadex for verapamil intoxication

Basic and Clinical Pharmacology and Toxicology

Volumn 113, Issue 4, 2013, Pages 280-285

  Ozbilgin, Sule ^a   Ozbilgin, Mucahit ^a   Kucukoztas, Beyza ^a   Kamaci, Gonca ^a   Unek, Tarkan ^a   Yurtlu, Bülent Serhan ^a   Ensari Güneli, Mehmet ^a   Hanci, Volkan ^a   Gunerli, Ali ^a  

^a DOKUZ EYLUL UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

SUGAMMADEX; VERAPAMIL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BREATHING RATE; CARDIOTOXICITY; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; DRUG SCREENING; ELECTROCARDIOGRAM; HEART ARREST; HEART RATE; LETHAL DOSE; NONHUMAN; PRIORITY JOURNAL; RAT;

ANIMALIA; RATTUS; RATTUS NORVEGICUS;

ANIMALS; CARDIOVASCULAR SYSTEM; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG EVALUATION, PRECLINICAL; DRUG INTERACTIONS; ELECTROCARDIOGRAPHY; GAMMA-CYCLODEXTRINS; HEART ARREST; HEART RATE; RATS; RATS, WISTAR; VERAPAMIL;

EID: 84883773204     PISSN: 17427835     EISSN: 17427843     Source Type: Journal    
DOI: 10.1111/bcpt.12089     Document Type: Article

References (43)

1. Centers for Disease Control and Prevention, National Center for Injury Prevention and Control. Web-based Injury Statistics Query and Reporting System (WISQARS), 2009, http://www.cdc.gov/injury/wisqars/ (last accessed on 1 May 2013).
2. Bronstein AC, Spyker DA, Cantilena LR, Rumack BH, Dart RC. 2011 Annual Report of the American Association of Poison Control Centers ' National Poison Data System (NPDS): 29th Annual Report. Clin Toxicol 2012;50:911-1164.
3. Yalçin Ş, Güntekin Ü, Sezen Y, Nacar H, Dalyan A. Yavaş Salinimli Verapamil İntoksikasyonu. Bidder Tip Bilimleri Dergisi 2010;2:29-31.
4. Olson KR. Poisoning and Drug Overdose 3rd edn, Appleton &Lange Stamford, Connecticut 1999, Calcium antagonists Benowittz NL 119-23.
5. Dustan HP. Calcium channel blockers. Potential medical benefits and side effects. Hypertension 1989;13:137-40.
6. Jeffrey B. Cardiovascular. In: Jeffrey B, Kevin W, Keith K Burkhart (eds). Critical Care Toxicology:Diagnosis and Management of the Critically Poisoned Patient, Vol III, Edition 1, 2004, 393-441.
7. Brass BJ, Winchester-Penny S, Lipper BL. Massive verapamil overdose complicated by noncardiogenic pulmonary edema. Am J Emerg Med 1996;14:459-61.
8. Mégarbane B, Karyo S, Abidi K, Delhotal-Landes B, Aout M, Sauder P et al. Predictors of mortality in verapamil overdose: usefulness of serum verapamil concentrations. Basic Clin Pharmacol Toxicol 2011;108:385-9.
9. Liang CW, Diamond SJ, Daniel SH. Lipid rescue of massive verapamil overdose: a case report. J Med Case Rep 2011;5:399.
10. Kimura Y, Okamura M, Harioka T, Hara T, Nakasato A, Ishiyama T et al. Suspected diltiazem intoxication resulting in repeated asystole after the induction of anesthesia. Masui 2012 Jan;61:104-7.
11. Janion M, Stepień A, Sielski J, Gutkowski W. Is the intra-aortic balloon pump a method of brain protection during cardiogenic shock after drug intoxication? J Emerg Med 2010 Feb;38:162-7.
12. Daubin C, Lehoux P, Ivascau C, Tasle M, Bousta M, Lepage O et al. Extracorporeal life support in severe drug intoxication: a retrospective cohort study of seventeen cases. Crit Care 2009;13:R138.
13. Rygnestad T, Moen S, Wahba A, Lien S, Ingul CB, Schrader H et al. Severe poisoning with sotalol and verapamil. Recovery after 4 h of normothermic CPR followed by extra corporeal heart lung assist. Acta Anaesthesiol Scand 2005 Oct;49:1378-80.
14. Young AC, Velez LI, Kleinschmidt KC. Intravenous fat emulsion therapy for intentional sustained-release verapamil overdose. Resuscitation 2009;80:591-3.
15. Montiel V, Gougnard T, Hantson P. Diltiazem poisoning treated with hyperinsulinemic euglycemia therapy and intravenous lipid emulsion. Eur J Emerg Med 2011;18:121-3.
16. ® therapy during treatment of an overdose. Clin Toxicol (Phila) 2011;49:340-4.
17. Zhanna L, Robert S. Hoffman response to: 'Intravenous Fat Emulsion Therapy: Can It be Tried Without Sufficient First-Line Treatment Modalities?' Basic Clin Pharmacol Toxicol 2012;111:3
18. Litonius E, Niiya 1T, Neuvonen PJ, Rosenberg PH. Antidotal effect of intravenous lipid emulsion in experimental amitriptyline intoxication despite significant entrapment of amitriptyline. Basic Clin Pharmacol Toxicol 2012;110:378-83.
19. Challa R, Ahuja A, Ali J, Khar RK. Cyclodextrins in drug delivery: an updated review. AAPS Pharm SciTech 2005;6:329-57.
20. Valentino JS, Quanren H. Cyclodextrins. Toxicologic Pathol 2008;36:30-42.
21. Mottram AR, Bryant SM, Steven E. Effect of cyclodextrin infusion in a rat model of verapamil toxicity. Am J Therap 2011;18:371-4.
22. Mottram AR, Bryant SM, Steven E. Dose-dependent response to cyclodextrin infusion in a rat model of verapamil toxicity. West J Emerg Med 2012;13:63-7.
23. Sacan O, White PF, Tufanogullari B, Klein K. Sugammadex reversal of Rocuronium-Induced neuromuscular blockade: a comparison with Neostigmine-Glycopyrrolate and Edrophonium-Atropine. Anesth Analg 2007;104:569-74.
24. Srivastava A, Hunter JM. Reversal of neuromuscular block. Br J Anaesth 2009;103:115-29.
25. Tebbutt S, Harvey M, Nicholson T. Intralipid prolongs survival in a rat model of verapamil toxicity. Acad Emerg Med 2006;13:134-9.
26. Tomak Y, Yilmaz A, Bostan H, Tümkaya L, Altuner D, Kalkan Y et al. Effects of sugammadex and rocuronium mast cell number and degranulation in rat liver. Anaesthesia 2012 Oct;67:1101-4.
27. Monteiro PF. Calcium channel antagonists: role in acute coronary syndromes therapy. European Heart J, ISSN 0195-668X, 08/2006, Cilt 27, 381.
28. Cardiac & Cardiovascular Systems. Calcium Antagonists. Ehud Ehud and Franz H. Messerli. Progress in Cardiovascular Diseases, ISSN 0033-0620, 07/2004, Vol 47, Edit: 1, 34-57.
29. Engebretsen KM, Kaczmarek KM, Morgan J. And. Holger J S - High dose insulin therapy in beta-blocker and calcium channel-blocker poisoning. Clinical Toxicol 2011;49:277-83.
30. Hofer CA, Smith JK, Tenholder MF. Verapamil intoxication: a literature review of overdoses and discussion of therapeutic options. Am J Med 1993 Oct;95:431-8.
31. Perez E, Bania TC, Medlej K, Chu J. Determining the optimal dose of intravenous fat emulsion for the treatment of severe verapamil toxicity in a rodent model. Acad Emerg Med 2008;15:1284-9.
32. Bania TC, Chu J, Perez E, Su M, Hahn IH. Hemodynamic effects of intravenous fat emulsion in an animal model of severe verapamil toxicity resuscitated with atropine, calcium, and saline. Acad Emerg Med 2007;14:105-11.
33. Kurola J, Leppikangas H, Magga J, Lindgren L, Kiviniemi V, Rutanen J, Ruokonen E. Effect of levosimendan in experimental verapamil induced myocardial depression. Scand J Trauma, Resus Emerg Med 2010;18:12.
34. Graudins A, Najafi J, Rur-Sc P. Treatment of experimental verapamil poisoning with levosimendan utilizing a rodent model of drug toxicity. Clinical Toxicol 2008;46:50-6.
35. Abraham MK, Scott SB, Meltzer A, Barrueto F. Levosimendan does not improve survival time in a rat model of verapamil toxicity. J Med Toxicol 2009;5:3-7.
36. Agoston S, Maestrone E, van Hezik EJ, Ket JM, Houwertjes MC, Uges DR. Effective treatment of verapamil intoxication with 4-aminopyridine in the cat. J Clin Invest 1984 May;73:1291-6.
37. Naguib M. Sugammadex: another milestone in clinical neuromuscular pharmacology. Anesth Analg 2007;104:575-81.
38. Hanci V, Kiraz HA, Ömür D, Ekin S, Uyan B, Yurtlu S. Precipitation in Gallipoli: Sugammadex/Amiadoron & Sugammadex/Dobutamin & Sugammadex/Protamin. Brazillian J Anesthesiol 2013;63:163-4.
39. Zhang M-Q. - Drug-specific cyclodextrins: the future of rapid neuromuscular block reversal? Drugs Future 2003;28:347-54.
40. Kalkan Y, Bostan H, Tumkaya L, Tomak Y, Bostan M, Yilmaz A, Turut H, Temiz A, Yalçin A, Turan A. The effect of rocuronium, sugammadex, and their combination on cardiac muscle and diaphragmatic skeletal muscle cells. J Anesth 2012 Dec;26:870-7.
41. Kalkan Y, Tümkaya L, Bostan H, Tomak Y, Yilmaz A. Effects of sugammadex on immunoreactivity of calcineurin in rat testes cells after neuromuscular block: a pilot study. J Mol Histol 2012; 43:235-41.
42. Tanaka K, Oda Y, Funao T, Takahashi R, Hamaoka N, Asada A. Dexmedetomidine decreases the convulsive potency of bupivacaine. and levobupivacaine in rats: involvement of α-2 adrenoceptor for controlling convulsions. Anesth Analg 2005;100:687-96.
43. Rosen MA, Thigpen JW, Shnider SM, Foutz SE, Levinson G, Koike M. Bupivacaine-induced cardiotoxicity in hypoxic and acidotic sheep. Anesth Analg 1985;64:1089-109.